Celera Gets Value from Proteomics Via Partnerships and Improved Data Analysis | GenomeWeb

Celera Genomics still hopes to get value out of its proteomics effort by trying to turn proteins into drug targets or diagnostics. Last month, Abbott became the first company to begin validating Celera's cell-surface antigens with two proteins from the company's proteomics program.

Almost a year after Celera signed its first partnerships with Abbott, GE (see PM 7/16/04), and later, Seattle Genetics and Genentech, the company is still validating targets it discovered internally.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.